Ted: 7 May possibly 2013 Published: 14 MayReferences 1. Berger JR, Concha M: Progressive multifocal leukoencephalopathy: the evolution of a illness when regarded uncommon, J. Neurovirology 1995, 1(1):five?8. 2. Miller JR, Barrett RE, Britton CB, Tapper ML, Bahr GS, Bruno PJ, Marquardt MD, Hays AP, McMurtry JG 3rd, Weissman JB, Bruno MS: Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med 1982, 307(23):1436?438. three. Safak M, Major E, Khalili K: Human polyomavirus, JC virus, and progressive multifocal encephalopathy. Inside the Neurology of AIDS. Edited by I.G. Howard, E. Gendelman, Ian Paul Everall, Stuart A. Lipton and Susan Swindell. New York: Oxford University Press; 2005:461?74. four. Berger JR, Khalili K: The pathogenesis of progressive multifocal leukoencephalopathy. Discov Med 2011, 12(67):495?03. 5. Eng PM, Turnbull BR, Cook SF, Davidson JE, Kurth T, Seeger JD: Traits and antecedents of progressive multifocal leukoencephalopathy in an insured population.Price of 1783407-55-5 Neurology 2006, 67(five):884?86. six. Padgett BL, Zu Rhein GM, Walker DL, Echroade R, Dessel B: Cultivation of papova-like virus from human brain with progressive multifocal leukoencephalopathy. Lancet 1971, 1(7712):1257?260. 7. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005, 353(4):375?81. eight. Moens U, Johannessen M: Human polyomaviruses and cancer: expanding repertoire. J Dtsch Dermatol Ges 2008, six(9):704?08. 9. Kleinschmidt-DeMasters BK, Tyler KL: Progressive multifocal leukoencephalopathy complicating therapy with natalizumab and interferon beta-1a for a number of sclerosis. N Engl J Med 2005, 353(four):369?74. ten. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P: Natalizumab induction and upkeep therapy for Crohn’s illness. International Efficacy of Natalizumab as Active Crohn’s Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. N Engl J Med 2005, 353(four):375?81. 11. Frisque RJ, Bream GL, Cannella MT: Human polyomavirus JC virus genome. J Virol 1984, 51(two):458?69. 12. Jensen PM, Main EO: A classification scheme for human polyomavirus JCV variants primarily based around the nucleotide sequence on the noncoding regulatory region. J Neurovirol 2001, 7(four):280?87. 13. White MK, Safak M, Khalili K: Regulation of gene expression in primate polyomaviruses. J Virol 2009, 83(21):10846?0856. 14. Sariyer IK, Khalili K: Regulation of human neurotropic polyomavirus, JCV, by option splicing aspect, SF2/ASF, in glial cells.14592-56-4 Formula PLoS One 2011, 6(1):e14630.PMID:24732841 15. Markowitz RB, Eaton BA, Kubik MF, Latorra D, McGregor JA, Dynan WS: BK virus and JC virus shed in the course of pregnancy have predominantly archetypal regulatory regions. J Virol 1991, 65(8):4515?519. 16. Daniel AM, Swenson JJ, Mayreddy RP, Khalili K, Frisque RJ: Sequences within the early and late promoters of archetype JC virus restrict viral DNA replication and infectivity. Virology 1996, 216(1):90?01. 17. Vaz B, Cinque P, Pickhardt M, Weber T: Analysis with the transcriptional control area in progressive multifocal leukoencephalopathy. J Neurovirol. Oct; 2000, six(5):398?09. 18. Pietropaolo V, Videtta M, Fioriti D, Mischitelli M, Arancio A, Orsi N, Degener AM: Rearrangement patterns of JC virus noncoding handle region from diffe.